RU2770050C2 - Способ лечения с применением традипитанта - Google Patents

Способ лечения с применением традипитанта Download PDF

Info

Publication number
RU2770050C2
RU2770050C2 RU2017134443A RU2017134443A RU2770050C2 RU 2770050 C2 RU2770050 C2 RU 2770050C2 RU 2017134443 A RU2017134443 A RU 2017134443A RU 2017134443 A RU2017134443 A RU 2017134443A RU 2770050 C2 RU2770050 C2 RU 2770050C2
Authority
RU
Russia
Prior art keywords
tradipitant
day
atopic dermatitis
dose
plasma concentration
Prior art date
Application number
RU2017134443A
Other languages
English (en)
Russian (ru)
Other versions
RU2017134443A3 (enExample
RU2017134443A (ru
Inventor
Михаэль Х. ПОЛИМЕРОПОУЛОС
Луис Уилльям ЛИКАМЕЛЕ
Original Assignee
Ванда Фармасьютиклз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ванда Фармасьютиклз Инк. filed Critical Ванда Фармасьютиклз Инк.
Publication of RU2017134443A publication Critical patent/RU2017134443A/ru
Publication of RU2017134443A3 publication Critical patent/RU2017134443A3/ru
Application granted granted Critical
Publication of RU2770050C2 publication Critical patent/RU2770050C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Encapsulation Of And Coatings For Semiconductor Or Solid State Devices (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Steroid Compounds (AREA)
  • Eye Examination Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2017134443A 2015-03-04 2016-03-04 Способ лечения с применением традипитанта RU2770050C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562128472P 2015-03-04 2015-03-04
US62/128,472 2015-03-04
US201562232644P 2015-09-25 2015-09-25
US62/232,644 2015-09-25
PCT/US2016/021015 WO2016141341A1 (en) 2015-03-04 2016-03-04 Method of treatment with tradipitant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2022102184A Division RU2810253C2 (ru) 2015-03-04 2016-03-04 Способ лечения с применением традипитанта

Publications (3)

Publication Number Publication Date
RU2017134443A RU2017134443A (ru) 2019-04-04
RU2017134443A3 RU2017134443A3 (enExample) 2019-09-05
RU2770050C2 true RU2770050C2 (ru) 2022-04-14

Family

ID=55629110

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017134443A RU2770050C2 (ru) 2015-03-04 2016-03-04 Способ лечения с применением традипитанта

Country Status (19)

Country Link
US (6) US10463655B2 (enExample)
EP (2) EP3265087B1 (enExample)
JP (4) JP6891385B2 (enExample)
KR (3) KR102860817B1 (enExample)
CN (2) CN113262221A (enExample)
AU (4) AU2016226006B2 (enExample)
BR (1) BR112017018620A2 (enExample)
CA (2) CA3213864A1 (enExample)
CL (1) CL2017002238A1 (enExample)
DK (1) DK3265087T3 (enExample)
ES (1) ES2824552T3 (enExample)
HR (1) HRP20201627T1 (enExample)
HU (1) HUE050944T2 (enExample)
IL (1) IL254142B (enExample)
MX (2) MX385788B (enExample)
PT (1) PT3265087T (enExample)
RU (1) RU2770050C2 (enExample)
WO (1) WO2016141341A1 (enExample)
ZA (1) ZA201706059B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102860817B1 (ko) * 2015-03-04 2025-09-16 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피턴트에 의한 치료 방법
CN111093671A (zh) * 2017-09-13 2020-05-01 万达制药公司 以托吡坦对特应性皮炎的改进治疗
ES3032138T3 (en) * 2017-11-17 2025-07-15 Vanda Pharmaceuticals Inc Tradipitant for use in treating gastroparesis
CA3101210A1 (en) * 2018-06-08 2019-12-12 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
JP7468964B2 (ja) * 2018-09-28 2024-04-16 バンダ・ファーマシューティカルズ・インコーポレイテッド 動揺病におけるトラジピタントの使用
US20220096449A1 (en) * 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2020132513A1 (en) 2018-12-21 2020-06-25 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
CN115052599A (zh) * 2020-02-25 2022-09-13 万达制药公司 以川地匹坦对特应性皮炎的改进治疗
US20230145932A1 (en) * 2020-03-26 2023-05-11 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
KR20250123807A (ko) 2022-12-21 2025-08-18 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 치료 방법
US20250255855A1 (en) 2024-02-09 2025-08-14 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091226A1 (en) * 2002-04-26 2003-11-06 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305718D0 (en) 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
TW263498B (enExample) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
GB9513972D0 (en) 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
ES2226622T3 (es) 1999-02-24 2005-04-01 F. Hoffmann-La Roche Ag Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1.
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
DK1501808T3 (da) * 2002-04-26 2008-10-13 Lilly Co Eli Tachykininreceptor-antagonister
JP2004250329A (ja) 2002-12-26 2004-09-09 Dainippon Pharmaceut Co Ltd イサチン誘導体
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
BRPI0415010B8 (pt) * 2003-10-24 2021-05-25 Lilly Co Eli formas cristalinas iv e v de {2-[1-(3,5-bis-trifluorometilbenzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il)-(2-clorofenil)-metanona, (2-clorofenil)-[2-(2-hidróxi-2-piridin-4-il-vinil)piridin-3-il]metanona, seus processos de preparação, e composição farmacêutica sólida
JP4673068B2 (ja) 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Ｔｈ１型アレルギー疾患治療用組成物
DE102005006217B4 (de) 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
CA2643130A1 (en) 2006-02-22 2007-08-30 Valorisation Recherche Hscm, Limited Partnership Compounds and methods of treating disorders associated with activation of metachromatic cells
JP5443168B2 (ja) * 2006-12-20 2014-03-19 イーライ リリー アンド カンパニー ｛２−［１−（３，５−ビス−トリフルオロメチル−ベンジル）−５−ピリジン−４−イル−１ｈ−［１，２，３］トリアゾール−４−イル］−ピリジン−３−イル｝−（２−クロロフェニル）−メタノンの調製において有用な新規の中間体及び方法
CN105503870A (zh) 2009-08-14 2016-04-20 欧科生医股份有限公司 神经激肽-1拮抗剂的静脉内制剂
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
RS53491B1 (sr) 2009-11-18 2015-02-27 Helsinn Healthcare Sa Kompozicije za lečenje centralno posredovane mučnine i povraćanja
EP2931253A1 (en) 2012-12-13 2015-10-21 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
JP6644328B2 (ja) 2013-02-28 2020-02-12 ロート製薬株式会社 アトピー性疾患の発症又は重症化リスクの評価法
US8906951B1 (en) * 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
EP3013336A1 (en) * 2013-06-24 2016-05-04 Tigercat Pharma Inc. Use of nk-1 receptor antagonist serlopitant in pruritus
KR102860817B1 (ko) * 2015-03-04 2025-09-16 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피턴트에 의한 치료 방법
WO2016195723A1 (en) 2015-06-03 2016-12-08 Beller Pharmaceuticals LLC Methods of treatment for conditions mediated by substance p
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
RU2724053C2 (ru) 2015-11-30 2020-06-19 Анакор Фармасьютикалз, Инк. Фармацевтические составы для местного применения для лечения связанных с воспалением состояний
CN115531553A (zh) 2015-12-22 2022-12-30 武田药品工业株式会社 内体g蛋白-偶联的受体的三部分调节剂
CN111093671A (zh) * 2017-09-13 2020-05-01 万达制药公司 以托吡坦对特应性皮炎的改进治疗
ES3032138T3 (en) * 2017-11-17 2025-07-15 Vanda Pharmaceuticals Inc Tradipitant for use in treating gastroparesis
CA3101210A1 (en) * 2018-06-08 2019-12-12 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
JP7468964B2 (ja) * 2018-09-28 2024-04-16 バンダ・ファーマシューティカルズ・インコーポレイテッド 動揺病におけるトラジピタントの使用
US20220096449A1 (en) * 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091226A1 (en) * 2002-04-26 2003-11-06 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D. SANTINI MD et al., Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study, The Lancet Oncology Volume 13, Issue 10, October 2012, Pages 1020-1024, PMID: 22995650. *
TROWER MK et al., Neurokinin‐1 receptor antagonist orvepitant is an effective inhibitor of itch‐associated response in a Mongolian gerbil model of scratching behaviourVolume23, Issue11, November 2014, c. 858-860, PMID: 25078633. *
TROWER MK et al., Neurokinin‐1 receptor antagonist orvepitant is an effective inhibitor of itch‐associated response in a Mongolian gerbil model of scratching behaviourVolume23, Issue11, November 2014, c. 858-860, PMID: 25078633. D. SANTINI MD et al., Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study, The Lancet Oncology Volume 13, Issue 10, October 2012, Pages 1020-1024, PMID: 22995650. *

Also Published As

Publication number Publication date
JP2021073258A (ja) 2021-05-13
CN107427502B (zh) 2021-06-04
JP6891385B2 (ja) 2021-06-18
JP2024074963A (ja) 2024-05-31
CL2017002238A1 (es) 2018-04-20
US10463655B2 (en) 2019-11-05
ES2824552T3 (es) 2021-05-12
US20190290626A1 (en) 2019-09-26
DK3265087T3 (da) 2020-10-19
IL254142B (en) 2022-05-01
AU2025210905A1 (en) 2025-08-21
CA2978736C (en) 2023-11-07
KR20170122777A (ko) 2017-11-06
CA2978736A1 (en) 2016-09-09
MX2021010460A (es) 2021-09-21
JP2023052486A (ja) 2023-04-11
EP3265087B1 (en) 2020-07-22
HRP20201627T1 (hr) 2021-02-19
CN113262221A (zh) 2021-08-17
MX385788B (es) 2025-03-18
AU2023233141A1 (en) 2023-10-12
CA3213864A1 (en) 2016-09-09
ZA201706059B (en) 2023-08-30
US11324735B2 (en) 2022-05-10
KR20230173743A (ko) 2023-12-27
US20250205213A1 (en) 2025-06-26
JP2018507243A (ja) 2018-03-15
US10772880B2 (en) 2020-09-15
CN107427502A (zh) 2017-12-01
US20180110761A1 (en) 2018-04-26
HUE050944T2 (hu) 2021-01-28
RU2017134443A3 (enExample) 2019-09-05
PT3265087T (pt) 2020-10-15
IL254142A0 (en) 2017-10-31
US20200360358A1 (en) 2020-11-19
KR102860817B1 (ko) 2025-09-16
US20220226295A1 (en) 2022-07-21
US12318375B2 (en) 2025-06-03
AU2016226006A1 (en) 2017-09-21
WO2016141341A1 (en) 2016-09-09
AU2023233141B2 (en) 2025-05-22
BR112017018620A2 (pt) 2018-04-17
AU2016226006B2 (en) 2021-03-04
US20190290625A1 (en) 2019-09-26
KR20250136946A (ko) 2025-09-16
EP3265087A1 (en) 2018-01-10
RU2017134443A (ru) 2019-04-04
MX2017011279A (es) 2018-01-25
AU2021202956A1 (en) 2021-06-03
NZ735121A (en) 2024-07-26
EP3730140A1 (en) 2020-10-28
HK1248552A1 (zh) 2018-10-19
AU2021202956B2 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
RU2770050C2 (ru) Способ лечения с применением традипитанта
AU2017315781B2 (en) Use of pridopidine for treating dystonias
Chase et al. Donepezil plus solifenacin (CPC-201) treatment for Alzheimer's disease
KR20090034810A (ko) 멜라토닌 효능제 치료
JP2016074728A (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
EA028060B1 (ru) Комбинированная терапия бокового амиотрофического склероза
RU2810253C2 (ru) Способ лечения с применением традипитанта
HK1248552B (en) Method of treatment with tradipitant
CN104906501A (zh) 治疗银屑病的中药组分组合物
WO2024211216A1 (en) Cilnidipine and a p-glycoprotein inhibitor for treating pain